Literature DB >> 19584658

Distortion maps from preferential hyperacuity perimetry are helpful in monitoring functional response to Lucentis therapy.

Radha Das1, Yanyun Shi, Guiliana Silvestri, Usha Chakravarthy.   

Abstract

PURPOSE: To use preferential hyperacuity perimetry to obtain a quantitative measure of central visual field distortion that would aid in the monitoring of functional responsiveness to ranibizumab treatment.
METHODS: This study is a retrospective analysis of data from patients with neovascular age-related macular degeneration treated with ranibizumab. Preferential hyperacuity perimetry (PHP) were performed before and within 10 days of treatment. Pre- and posttreatment PHP metamorphopsia maps of contours showing 6 levels of metamorphopsia severity (S1 through S6; least to most distortion) were analyzed. Optical coherence tomography (OCT) outputs were subjected to standardized grading to generate metrics on subretinal fluid height, maximum retinal thickness, outer high-reflectivity band thickness, and height of pigment epithelial detachment (OCT metrics).
RESULTS: Complete data were available from 17 patients. Statistically significant reductions were seen between baseline and posttreatment in PHP contour areas and OCT metrics, except for maximum retinal thickness. Mean best-corrected visual acuity improved by two letters, but this was not statistically significant. Change in PHP parameters correlated strongly with change in subretinal fluid height, with P values of <0.01 for most comparisons. Change in best-corrected visual acuity did not correlate with change in any of the OCT metrics or PHP distortion map areas.
CONCLUSION: The reduction in the contour map area seen on PHP outputs occurs rapidly and correlates with the resolution of subretinal fluid, suggesting that this parameter may be used to monitor response to therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19584658     DOI: 10.1097/IAE.0b013e3181a91dbf

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  5 in total

1.  The accuracy of home monitoring to detect disease activity during maintenance therapy for neovascular ARMD.

Authors:  Martin McKibbin; Lucy Baker; Paul Baxter; Carolyn Czoski-Muray; Roopa Setty
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-11-05       Impact factor: 3.117

2.  Environmental Amsler test as a monitoring tool for retreatment with ranibizumab for neovascular age-related macular degeneration.

Authors:  R Mathew; S Sivaprasad
Journal:  Eye (Lond)       Date:  2011-12-16       Impact factor: 3.775

3.  Randomized trial of a home monitoring system for early detection of choroidal neovascularization home monitoring of the Eye (HOME) study.

Authors:  Emily Y Chew; Traci E Clemons; Susan B Bressler; Michael J Elman; Ronald P Danis; Amitha Domalpally; Jeffrey S Heier; Judy E Kim; Richard Garfinkel
Journal:  Ophthalmology       Date:  2013-11-08       Impact factor: 12.079

4.  Visual performance in patients with neovascular age-related macular degeneration undergoing treatment with intravitreal ranibizumab.

Authors:  Sarah Sabour-Pickett; James Loughman; John M Nolan; Jim Stack; Konrad Pesudovs; Katherine A Meagher; Stephen Beatty
Journal:  J Ophthalmol       Date:  2013-02-21       Impact factor: 1.909

Review 5.  Quantitative physiological measurements to evaluate the response of antivascular endothelial growth factor treatment in patients with neovascular diseases.

Authors:  In Hwan Hong; Sung Pyo Park
Journal:  Indian J Ophthalmol       Date:  2017-07       Impact factor: 1.848

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.